Friday, May 10, 2024 11:31:51 AM
Recent ARQT News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 09:12:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 07:58:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:06:16 PM
- Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/14/2024 08:00:00 PM
- US Futures Remain Steady Amid Wall Street Caution Ahead of April PPI Report • IH Market News • 05/14/2024 11:18:01 AM
- Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology • GlobeNewswire Inc. • 05/13/2024 12:00:00 PM
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/03/2024 08:00:00 PM
- Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 • GlobeNewswire Inc. • 04/29/2024 08:00:00 PM
- Arcutis Appoints David Topper as Chief Financial Officer • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/05/2024 08:00:00 PM
- Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream • GlobeNewswire Inc. • 04/01/2024 11:00:00 AM
- Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/28/2024 12:00:00 PM
- Arcutis Promotes Todd Tucker to Chief Human Resources Officer • GlobeNewswire Inc. • 03/11/2024 12:00:00 PM
- Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting • GlobeNewswire Inc. • 03/10/2024 08:00:00 PM
- New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction • GlobeNewswire Inc. • 03/09/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:14:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:09:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:08:24 PM
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/05/2024 09:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 10:47:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 10:42:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 10:40:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:10:37 PM
- Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares • GlobeNewswire Inc. • 03/04/2024 09:00:00 PM
- Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM